SHANGHAI, June 14 (Reuters) - A second Chinese drugmaker has applied for approval to sell a generic version of Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic in China.
BEIJING, Sept 2 (Reuters) - China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's COVID-19 vaccine as a booster, the company said on Friday, one of just two new products against the disease the country has cleared in more than a year.
Livzon Pharmaceutical Group was recognized as the National Enterprise Technology Center with High Scores
A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
A potential COVID-19 vaccine developed by a subsidiary of China's Livzon Pharmaceutical Group Inc appeared safe and able to elicit antibodies in healthy adults in a mid-stage clinical trial, Chinese researchers said.
BEIJING (Reuters) - China’s medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc, the Chinese company said late on Tuesday.
Livzon participated in the 39th Annual JP Morgan Medical Health Conference
LTS Lohmann Therapie-Systeme AG (“LTS”), a world class pharmaceutical technology company headquartered in Andernach, Germany, and Livzon Pharmaceutical Group Inc. (000513.SZ,1513.HK) (“Livzon”), a leading PRC pharmaceutical company, announced today that the companies have entered into an exclusive license and collaboration agreement (the “Agreement”). LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).